Tumor Immunotherapy Innovation Team

1. creating humanized tumor model associated with human tumor;

2. selecting new specific antigens of nasopharynx cancer, liver cancer, and glioma, and highly specific human monoclonal antibody;

3. developing new strategies of using human monoclonal antibodies in tumor immunotherapy via the Ab－INF method, over which the team has intellectual property right;

4. developing new methods of using anti-tumor specific antigen-ScFv/CD3ζ-CAR T cell;

5. applying for 1-2 international patents and 3-5 national patents;

6. conducting technological transfer and clinical experiments so as to bring China’s tumor immunotherapy to the frontier of international tumor drug innovation system.